RecruitingNCT05927558

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Salvage Treatment With Glofitamab in Patients Affected by Relapsed/Refractory Non-Hodgkin B-cell Lymphoma: a GIMEMA-FIL Study

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Enrollment

96 participants

Start Date

Dec 22, 2023

Study Type

OBSERVATIONAL

Conditions

Relapse B-cell Non Hodgkin Lymphoma Refractory Lymphoma

Summary

The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with b-cell non hodgkin lymphoma, refractory lymphoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Ematologia Istituto Nazionale Tumori

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05927558

Related Trials

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT0656403864 locations

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT072206166 locations